Abstract 458P
Background
Analysis of ctDNA in operable NSCLC for the identification of patients at high risk of relapse could allow tailoring of adjuvant therapy with EGFR tyrosine kinase inhibitors (TKIs). We assessed whether tracking of EGFR mutations in plasma circulating tumor DNA (ctDNA) predicts relapse in completely resected EGFR-mutant NSCLC.
Methods
A prospective cohort of 45 EGFR-mutant stage I-IIIB NSCLC patients, all of whom underwent complete resection of their tumors, had plasma samples for ctDNA analysis taken post-surgery and in follow-up. Cobas EGFR Mutation Test (cobas) was used for tissue genotyping of the baseline tumor biopsy or surgical specimens, and droplet digital PCR (ddPCR) was performed to track the identified EGFR mutations in ctDNA.
Results
We identified EGFR exon 19 deletions (n = 23), L858R (n = 18), and L861Q (n = 4) mutations by cobas in pre-surgical tissue biopsies and/or surgical specimens, and used ddPCR assays for each EGFR mutation to measure ctDNA after surgery. Detection of ctDNA after complete tumor resection in 11 of 45 (24%) patients significantly predicted clinical relapse (hazard ratio [HR] 7.0, 95% confidence interval [CI] 2.13 to 22.68; log-rank p = 0.001). Multivariable analysis demonstrated that detection of ctDNA remained a significant predictor of clinical relapse after adjusting for clinical factors (HR 6.16, 95% CI 1.80 to 21.06; p = 0.004). Notably, ctDNA-based molecular relapse demonstrated a lead time of up to 8.1 months over clinical relapse.
Conclusions
Tracking of EGFR mutations in cfDNA following surgical treatment can identify NSCLC patients at high risk of relapse. Whether ctDNA monitoring could allow tailoring of adjuvant therapy with EGFR tyrosine kinase inhibitors will have to be determined in future clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
M. Filipits: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim. M.J. Hochmair: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim. A. Buder: Honoraria (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
Presenter: Wataru Goto
Session: Poster display session
Resources:
Abstract
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract